The myeloid cell leukaemia-1 inhibitor MIK665 is a potent therapy in preclinical models of paediatric acute myeloid leukaemia.
Saved in:
| Title: | The myeloid cell leukaemia-1 inhibitor MIK665 is a potent therapy in preclinical models of paediatric acute myeloid leukaemia. |
|---|---|
| Authors: | Connerty P; Children's Cancer Institute, Lowy Cancer Research Centre, School of Clinical Medicine, UNSW Medicine & Health, UNSW Centre for Childhood Cancer Research, UNSW Sydney, Sydney, New South Wales, Australia., Colgan JN; Children's Cancer Institute, Lowy Cancer Research Centre, School of Clinical Medicine, UNSW Medicine & Health, UNSW Centre for Childhood Cancer Research, UNSW Sydney, Sydney, New South Wales, Australia.; Kids Cancer Centre, Sydney Children's Hospital, Randwick, New South Wales, Australia.; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.; Department of Pediatrics, University of Washington, Seattle, WA, USA., El-Najjar F; Children's Cancer Institute, Lowy Cancer Research Centre, School of Clinical Medicine, UNSW Medicine & Health, UNSW Centre for Childhood Cancer Research, UNSW Sydney, Sydney, New South Wales, Australia., Henry E; Children's Cancer Institute, Lowy Cancer Research Centre, School of Clinical Medicine, UNSW Medicine & Health, UNSW Centre for Childhood Cancer Research, UNSW Sydney, Sydney, New South Wales, Australia., Xie J; Children's Cancer Institute, Lowy Cancer Research Centre, School of Clinical Medicine, UNSW Medicine & Health, UNSW Centre for Childhood Cancer Research, UNSW Sydney, Sydney, New South Wales, Australia., Idais D; Faculty of Engineering and IT, University of Technology Sydney, Sydney, New South Wales, Australia.; Cardiovascular Regeneration Group, Heart Research Institute, Newtown, New South Wales, Australia., Gentile C; Faculty of Engineering and IT, University of Technology Sydney, Sydney, New South Wales, Australia.; Cardiovascular Regeneration Group, Heart Research Institute, Newtown, New South Wales, Australia., Mao J; Children's Cancer Institute, Lowy Cancer Research Centre, School of Clinical Medicine, UNSW Medicine & Health, UNSW Centre for Childhood Cancer Research, UNSW Sydney, Sydney, New South Wales, Australia., Dolman MEM; Children's Cancer Institute, Lowy Cancer Research Centre, School of Clinical Medicine, UNSW Medicine & Health, UNSW Centre for Childhood Cancer Research, UNSW Sydney, Sydney, New South Wales, Australia., Marshall GM; Children's Cancer Institute, Lowy Cancer Research Centre, School of Clinical Medicine, UNSW Medicine & Health, UNSW Centre for Childhood Cancer Research, UNSW Sydney, Sydney, New South Wales, Australia.; Kids Cancer Centre, Sydney Children's Hospital, Randwick, New South Wales, Australia., Lock RB; Children's Cancer Institute, Lowy Cancer Research Centre, School of Clinical Medicine, UNSW Medicine & Health, UNSW Centre for Childhood Cancer Research, UNSW Sydney, Sydney, New South Wales, Australia. |
| Source: | British journal of haematology [Br J Haematol] 2026 Jun 04. Date of Electronic Publication: 2026 Jun 04. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 0372544 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1365-2141 (Electronic) Linking ISSN: 00071048 NLM ISO Abbreviation: Br J Haematol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
